Where does J&J's new drug fit in the crowded HIV market?

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Jul 18, 2018 at 10:02 PM.

  1. #1 cafead, Jul 18, 2018 at 10:02 PM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,979
    Likes Received:
    3
    via Johnson & Johnson's research unit Janssen Pharmaceuticals said Tuesday that U.S. regulators approved the once-daily medicine Symtuza for adult HIV patients who are either treatment-naive or virologically suppressed on a stable antiretroviral regimen. Symtuza carries a black box warning for post-treatment acute exacerbation of hepatitis B — an oft-cited caution with HIV drugs.

    article source
     
    Quote

Reply to Thread